期刊
ARCHIVES OF NEUROLOGY
卷 68, 期 12, 页码 1514-1520出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2011.914
关键词
-
资金
- Bayer Schering Pharma
- Biogen-Dompe
- Genmab A/S
- Merck Serono
- Teva Pharmaceutical Industries Ltd
- Fondazione Italiana Sclerosi Multipla
Magnetic resonance imaging (MRI) is sensitive to focal multiple sclerosis (MS) lesions. For this reason, conventional MRI measures of the burden of disease derived from dual-echo, fluid-attenuated inversion recovery and postcontrast T1-weighted sequences are regularly used to monitor disease course in patients with confirmed MS and have been included in the diagnostic workup of patients in whom MS is suspected. Other quantitative magnetic resonance (MR)-based techniques with a higher pathological specificity (including magnetization transfer-MRI, diffusion tensor-MRI, and proton MR spectroscopy) have been extensively applied to measure disease burden within focal visible lesions and in the normal-appearing white matter and gray matter of MS patients at different stages of the disease. These methods, combined with functional imaging techniques, are progressively improving our understanding of the factors associated with MS evolution. More recently, the application of new imaging modalities capable of measuring pathological processes related to the disease that have been neglected in the past (eg, iron deposition and perfusion abnormalities) and the advent of high-and ultrahigh-field magnets have provided further insight into the pathobiological features of MS. After a brief summary of the main results obtained from the established and emerging MR methods, this review discusses the steps needed before the latter become suitable for widespread use in the MS research community. Arch Neurol. 2011; 68(12): 1514-1520
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据